A striking and unexpected pharmacologic synergy has been shown between antagonist actions at serotonergic 5HT2C receptors, and agonist actions at melatonergic receptors by agomelatine, a drug that has both of these properties.
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ISSUE:
A striking and unexpected pharmacologic synergy has been shown between antagonist actions at serotonergic 5HT2C receptors, and agonist actions at melatonergic receptors by agomelatine, a drug that has both of these properties.
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Take-Home Points 1. Blocking serotonergic 5HT2C receptors causes the enhanced release of both dopamine and norepinephrine in the prefrontal cortex.
2.
Stimulating melatonergic MT1 and MT2 receptors causes synchronization of circadian rhythms.
3. When 5HT2C antagonism is combined with MT1 and MT2 agonism, this results in unexpected synergistic actions, including much greater dopamine and norepinephrine release in the prefrontal cortex than with 5HT2C antagonism alone, as well as several actions not seen at all with either action alone, including increases in brain derived neurotrophic factor (BDNF) in the prefrontal cortex, and reduction of stress-induced glutamate release in the amygdala.
4.
In theory, this synergy accounts for the antidepressant actions of the monoaminergic/ melatonergic agent agomelatine and may account for its unique clinical profile.
The new antidepressant agomelatine, marketed in many countries but not in the U.S., has a mechanism of action quite different from any other antidepressant. 1,2 It combines antagonist actions at serotonergic 5HT2C receptors with agonist actions at melatonergic MT1 and MT2 receptors ( Figure 1 ). Neither mechanism alone has any evidence of efficacy in depression, but when combined in a single molecule, agomelatine has proven antidepressant actions.
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Pharmacologic Synergy of Agomelatine
Normally, 5HT2C receptors inhibit downstream dopamine and norepinephrine release from the prefrontal cortex ( Figure 2A ). 1 When these 5HT2C receptors are blocked, dopamine and norepinephrine release is disinhibited in the prefrontal cortex, and the levels of dopamine and norepinephrine increase ( Figure 2B ). 5HT2C antagonist action is one of the multiple pharmacologic properties of many antidepressants, and may thus contribute to the antidepressant efficacy of quetiapine, olanzapine, mirtazapine, and possibly asenapine; some tricyclic antidepressants; and other known antidepressants. 1 Normally, stimulating melatonergic receptors has the effect of ''resynchronizing'' circadian rhythms 1, 2 without altering monoamines. However, when MT1/ MT2 stimulation is combined with 5HT2C antagonism, a striking and unexpected potentiation of dopamine and norepinephrine release occurs in the prefrontal cortex ( Figure 3) . 5 This is not the only example of synergy between these 2 mechanisms. A serendipitous finding of synergy between 5HT2C antagonism and MT1/MT2 agonism has now been demonstrated as well for increases in brain derived neurotrophic factor (BDNF) ( 
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It is also possible that separate actions in different brain areas may also account for some of the observed pharmacologic synergies. Where these various receptors exist in close physical contact, there is even the possibility of interaction of the receptors through heterodimerization. 2 However, the exact mechanism of how simultaneous actions at 5HT2C and MT1/ MT2 receptors is synergistic remains under active investigation.
Monoaminergic-Melatonergic Synergy and the Clinical Profile of Agomelatine
To the extent that restoring dopamine and norepinephrine neurotransmission results in antidepressant action, this may explain in part the antidepressant mechanism of agomelatine, which combines 5HT2C antagonism with MT1/MT2 agonism ( Figure 1 ). 1, 8 Indeed, this could theoretically underlie the observation BRAINSTORMS-Clinical Neuroscience Update Figure 2A . Serotonin normally inhibits dopamine (DA) and norepinephrine (NE) release via agonist actions at 5HT2C receptors. Serotonergic 5HT2C receptors on GABA-ergic interneurons in the brainstem normally inhibit the release of both dopamine and norepinephrine. . The unique synergy of agomelatine is necessary to increase BDNF in prefrontal cortex. Agomelatine increases brain derived neurotrophic factor (BDNF) in the prefrontal cortex. This is a unique product of both of agomelatine's pharmacologic actions since BDNF is not increased either by a selective 5HT2C antagonist or by melatonin, and agomelatine's actions on BDNF are reversed by a melatonin antagonist. Thus, the 5HT2C antagonist plus MT1/MT2 agonist actions of agomelatine are synergistic for causing increases in prefrontal BDNF. 
